Compare PBHC & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | LONA |
|---|---|---|
| Founded | 1859 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 81.5M |
| IPO Year | 2014 | 2020 |
| Metric | PBHC | LONA |
|---|---|---|
| Price | $16.27 | $8.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 4.6K | ★ 9.3K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $4.21 |
| 52 Week High | $17.40 | $14.21 |
| Indicator | PBHC | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 55.06 |
| Support Level | $15.50 | $7.96 |
| Resistance Level | $17.14 | $8.42 |
| Average True Range (ATR) | 0.34 | 0.43 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 45.71 | 85.63 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.